Literature DB >> 34315491

Identification of the miRNA signature and key genes in colorectal cancer lymph node metastasis.

Xi Wang1, Guangyu Gao2, Zhengrong Chen3, Zhihao Chen4, Mingxiao Han1, Xiaolu Xie1, Qiyuan Jin1, Hong Du1, Zhifei Cao5, Haifang Zhang6.   

Abstract

BACKGROUND: Because its metastasis to the lymph nodes are closely related to poor prognosis, miRNAs and mRNAs can serve as biomarkers for the diagnosis, prognosis, and therapy of colorectal cancer (CRC). This study aimed to identify novel gene signatures in the lymph node metastasis of CRC.
METHODS: GSE56350, GSE70574, and GSE95109 datasets were downloaded from the Gene Expression Omnibus (GEO) database, while data from 569 colorectal cancer cases were also downloaded from The Cancer Genome Atlas (TCGA) database. Differentially expressed miRNAs (DE-miRNAs) were calculated using R programming language (Version 3.6.3), while gene ontology and enrichment analysis of target mRNAs were performed using FunRich ( http://www.funrich.org ). Furthermore, the mRNA-miRNA network was constructed using Cytoscape software (Version 3.8.0). Gene expression levels were verified using the GEO datasets. Similarly, quantitative real-time PCR (qPCR) was used to examine expression profiles from 20 paired non-metastatic and metastatic lymph node tissue samples obtained from patients with CRC.
RESULTS: In total, five DE-miRNAs were selected, and 34 mRNAs were identified after filtering the results. Moreover, two key miRNAs (hsa-miR-99a, hsa-miR-100) and one gene (heparan sulfate-glucosamine 3-sulfotransferase 2 [HS3ST2]) were identified. The GEO datasets analysis and qPCR results showed that the expression of key miRNA and genes were consistent with that obtained from the bioinformatic analysis. A novel miRNA-mRNA network capable of predicting the prognosis and confirmed experimentally, hsa-miR-99a-HS3ST2-hsa-miR-100, was found after expression analysis in metastasized lymph node tissue from CRC samples.
CONCLUSION: In summary, miRNAs and genes with potential as biomarkers were found and a novel miRNA-mRNA network was established for CRC lymph node metastasis by systematic bioinformatic analysis and experimental validation. This network may be used as a potential biomarker in the development of lymph node metastatic CRC.
© 2021. The Author(s).

Entities:  

Keywords:  Colorectal cancer; HS3ST2; Lymph node metastasis; MicroRNA; Prognostic signature

Year:  2021        PMID: 34315491     DOI: 10.1186/s12935-021-02058-9

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  41 in total

1.  [Postoperative emergencies].

Authors:  T Montariol
Journal:  Soins Chir       Date:  1981-06

Review 2.  Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions.

Authors:  Steven L Bosch; Steven Teerenstra; Johannes H W de Wilt; Chris Cunningham; Iris D Nagtegaal
Journal:  Endoscopy       Date:  2013-07-24       Impact factor: 10.093

Review 3.  Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer.

Authors:  Scott R Steele; George J Chang; Samantha Hendren; Marty Weiser; Jennifer Irani; W Donald Buie; Janice F Rafferty
Journal:  Dis Colon Rectum       Date:  2015-08       Impact factor: 4.585

4.  let-7 microRNA functions as a potential growth suppressor in human colon cancer cells.

Authors:  Yukihiro Akao; Yoshihito Nakagawa; Tomoki Naoe
Journal:  Biol Pharm Bull       Date:  2006-05       Impact factor: 2.233

5.  The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer.

Authors:  Jon D Vogel; Cagla Eskicioglu; Martin R Weiser; Daniel L Feingold; Scott R Steele
Journal:  Dis Colon Rectum       Date:  2017-10       Impact factor: 4.585

6.  hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide.

Authors:  Evan E Kania; Jessika Carvajal-Moreno; Victor A Hernandez; Anthony English; Jonathan L Papa; Nicholas Shkolnikov; Hatice Gulcin Ozer; Ayse Selen Yilmaz; Jack C Yalowich; Terry S Elton
Journal:  Mol Pharmacol       Date:  2019-12-13       Impact factor: 4.436

Review 7.  Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.

Authors:  Thomas K Sin; Fengfeng Wang; Fei Meng; S C Cesar Wong; William C S Cho; Parco M Siu; Lawrence W C Chan; Benjamin Y M Yung
Journal:  Int J Mol Sci       Date:  2016-02-15       Impact factor: 5.923

Review 8.  The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer.

Authors:  Curt Balch; Jayaram B Ramapuram; Amit K Tiwari
Journal:  Front Pharmacol       Date:  2017-05-19       Impact factor: 5.810

9.  Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Authors:  R Dienstmann; M J Mason; F A Sinicrope; A I Phipps; S Tejpar; A Nesbakken; S A Danielsen; A Sveen; D D Buchanan; M Clendenning; C Rosty; B Bot; S R Alberts; J Milburn Jessup; R A Lothe; M Delorenzi; P A Newcomb; D Sargent; J Guinney
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

Review 10.  Research progress on the relationship between lung cancer drug-resistance and microRNAs.

Authors:  Xuan Ma; Ai-Ling Liang; Yong-Jun Liu
Journal:  J Cancer       Date:  2019-11-17       Impact factor: 4.207

View more
  2 in total

Review 1.  Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.

Authors:  Chunyan Zhang; Caifang Sun; Yabin Zhao; Qiwen Wang; Jianlin Guo; Bingyu Ye; Guoying Yu
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

2.  COL3A1 and Its Related Molecules as Potential Biomarkers in the Development of Human Ewing's Sarcoma.

Authors:  Min Tang; Peiqing Liu; Xiaoke Wu; Jie Gong; Jiacheng Weng; Guangyu Gao; Yulong Liu; Lei Gan
Journal:  Biomed Res Int       Date:  2021-12-22       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.